Innovation in breast cancer diagnosis
Molecular in vitro diagnostic test for the quantitative detection of the mRNA expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel recommends the use of four biomarkers for molecular subtyping of breast cancer:
- ERBB2 (HER2, human epidermal growth factor receptor 2)
- ESR1 (estrogen receptor 1)
- PGR (progesterone receptor)
- MKI67 (marker of proliferation Ki-67, a marker expressed in proliferating cells)
ERBB2 is the name of the gene for human epidermal growth factor receptor 2 (HER2). This receptor is a cell surface protein which belongs to the family of epidermal growth factor receptors. ERBB2 activation stimulates cell proliferation and inhibits programmed cell death. ERBB2 has an important role in breast cancer. About 20 % of all breast cancers show an overexpression of this receptor, which is associated with poor prognosis and clinical outcome.
In recent years numerous life-saving treatment options have been developed for the therapy of breast cancer. Today there is a wide selection of treatments available to fight each individual breast cancer type. For a personalized treatment recommendation different approaches are selected and combined based on a sound diagnosis.